These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 21750201)
1. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201 [TBL] [Abstract][Full Text] [Related]
2. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632 [TBL] [Abstract][Full Text] [Related]
3. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083 [TBL] [Abstract][Full Text] [Related]
4. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830 [TBL] [Abstract][Full Text] [Related]
5. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Naing A; Lorusso P; Fu S; Hong D; Chen HX; Doyle LA; Phan AT; Habra MA; Kurzrock R Br J Cancer; 2013 Mar; 108(4):826-30. PubMed ID: 23412108 [TBL] [Abstract][Full Text] [Related]
6. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715 [TBL] [Abstract][Full Text] [Related]
7. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280 [TBL] [Abstract][Full Text] [Related]
10. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838 [TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181 [TBL] [Abstract][Full Text] [Related]
12. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626 [TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780 [TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors. Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349 [TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248 [TBL] [Abstract][Full Text] [Related]
16. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641 [TBL] [Abstract][Full Text] [Related]
17. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305 [TBL] [Abstract][Full Text] [Related]
18. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]